Literature DB >> 17509774

Reactive oxygen species in cancer, too much or too little?

Fuxiong Lu1.   

Abstract

It is widely accepted that increased levels of reactive oxygen species (ROS) contribute to carcinogenesis. However, this claim has not been confirmed by experiments. On the contrary, a growing number of studies clearly demonstrate that ROS are normal cellular signals and induce cell differentiation and apoptosis, the opposite processes to cancer, which is dedifferentiated. Thus, it is hypothesized here that decreased levels of ROS may lead to cancer development, which is supported by following observations: (1) the fast-growing tumor produces ROS at a rate only one-third of the rate found with the control liver mitochondria; (2) the reduction in tumor mitochondrial content indicates low level of ROS production; (3) the low levels of manganese superoxide dismutase in tumor mitochondria also indicate decreased production of ROS, because the enzyme activity is induced by ROS; (4) lipid peroxidation capacity was decreased in human colon carcinomas and Yoshida hepatomas; (5) low levels of lipid peroxidation de-inhibit glucose-6-phosphate dehydrogenase, whose activity is always increased in a variety of cancers without exception. Clarification of real role of ROS in cancer may shed light on the understanding of how impairment of mitochondria leads to malignant transformation of normal cells, and offer new types of strategies for cancer prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509774     DOI: 10.1016/j.mehy.2007.03.017

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

Review 1.  ROS-induced ROS release in vascular biology: redox-redox signaling.

Authors:  Natalya S Zinkevich; David D Gutterman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-17       Impact factor: 4.733

2.  Silibinin ameliorates oxidative stress induced aberrant crypt foci and lipid peroxidation in 1, 2 dimethylhydrazine induced rat colon cancer.

Authors:  Nagarajan Sangeetha; Selvaraj Aranganathan; Namasivayam Nalini
Journal:  Invest New Drugs       Date:  2009-03-10       Impact factor: 3.850

Review 3.  Mitochondria and energetic depression in cell pathophysiology.

Authors:  Enn Seppet; Marju Gruno; Ants Peetsalu; Zemfira Gizatullina; Huu Phuc Nguyen; Stefan Vielhaber; Manfred H P Wussling; Sonata Trumbeckaite; Odeta Arandarcikaite; Doreen Jerzembeck; Maria Sonnabend; Katharina Jegorov; Stephan Zierz; Frank Striggow; Frank N Gellerich
Journal:  Int J Mol Sci       Date:  2009-05-19       Impact factor: 6.208

4.  Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma.

Authors:  Chen-Sung Lin; Hui-Ting Lee; Ming-Huei Lee; Siao-Cian Pan; Chen-Yeh Ke; Allen Wen-Hsiang Chiu; Yau-Huei Wei
Journal:  Int J Mol Sci       Date:  2016-05-25       Impact factor: 5.923

5.  Relative telomere length and oxidative DNA damage in hypertrophic ligamentum flavum of lumbar spinal stenosis.

Authors:  Sinsuda Dechsupa; Wicharn Yingsakmongkol; Worawat Limthongkul; Weerasak Singhatanadgige; Sittisak Honsawek
Journal:  PeerJ       Date:  2018-08-09       Impact factor: 2.984

6.  Decreased catalase expression is associated with ligamentum flavum hypertrophy due to lumbar spinal canal stenosis.

Authors:  Şeyho Cem Yücetaş; Tayfun Çakir
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Oxidative damage and carcinogenesis.

Authors:  Joanna Katarzyna Strzelczyk; Andrzej Wiczkowski
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06

8.  Hirsutanol A, a novel sesquiterpene compound from fungus Chondrostereum sp., induces apoptosis and inhibits tumor growth through mitochondrial-independent ROS production: hirsutanol A inhibits tumor growth through ROS production.

Authors:  Fen Yang; Wen-Dan Chen; Rong Deng; Hui Zhang; Jun Tang; Ke-Wei Wu; Dan-Dan Li; Gong-Kan Feng; Wen-Jian Lan; Hou-Jin Li; Xiao-Feng Zhu
Journal:  J Transl Med       Date:  2013-02-08       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.